ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Physician Assistant, Medical

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,835Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 42

$529K Total Retail Price of All Prescriptions

Rank: 2 out of 42

515 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
25% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

9% of this provider’s 515 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 8,328 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $70 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 8.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
LEVOTHYROXINE SODIUM 376 357 1 2
SIMVASTATIN 327 309 2 6
OMEPRAZOLE 294 276 3 7
CITALOPRAM HBR 240 226 4 32
NAMENDA 238 238 5 33
AMLODIPINE BESYLATE 212 212 6 1
FUROSEMIDE 198 186 7 8
LISINOPRIL 182 179 8 3
HYDROCODONE-ACETAMINOPHEN 166 149 S3 9 13
ESCITALOPRAM OXALATE 159 158 10 48
ATENOLOL 154 152 11 16
DONEPEZIL HCL 137 137 12 53
METOPROLOL TARTRATE 132 132 13 17
SERTRALINE HCL 131 124 14 56
MELOXICAM 128 120 15 12
HYDROCHLOROTHIAZIDE 117 104 16 15
BENAZEPRIL HCL 111 111 17 21
METFORMIN HCL 111 99 17 4
GLIMEPIRIDE 103 91 19 28
TRAZODONE HCL 93 86 20 68
METOPROLOL SUCCINATE 92 83 21 5
AZITHROMYCIN 91 83 22 35
ATORVASTATIN CALCIUM 87 78 23 9
CLONIDINE HCL 83 77 24 39
MIRTAZAPINE 82 81 25 72
NEXIUM 81 73 26 23
CLOPIDOGREL 76 69 27 20
PANTOPRAZOLE SODIUM 74 55 28 76
WARFARIN SODIUM 73 73 29 29
CARVEDILOL 73 60 29 14
POTASSIUM CHLORIDE 73 65 29 22
GABAPENTIN 72 65 32 11
CYMBALTA 70 69 33 59
EXELON 70 70 33 82
METHYLPREDNISOLONE 67 61 35 86
DIGOXIN 67 67 35 26
ALENDRONATE SODIUM 66 63 37 88
DIOVAN 66 66 37 34
TRAMADOL HCL 65 63 39 24
CRESTOR 64 59 40 18
PREDNISONE 63 52 41 36
ADVAIR DISKUS 62 56 42 92
BUMETANIDE 62 62 42 92
LEXAPRO 61 57 44 94
LEVOFLOXACIN 58 54 45 98
PLAVIX 58 54 45 31
ALLOPURINOL 55 54 47 100
AMLODIPINE BESYLATE-BENAZEPRIL 54 54 48 49
FLUTICASONE PROPIONATE 54 54 48 101
LOVASTATIN 53 53 50 41
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.